

Telmisartan Market: Growing Demand for Effective Hypertension Management | Says Evolve Business Intelligence

The Telmisartan Market, valued at USD 3.54 billion in 2023, is expected to grow at a compound annual growth rate (CAGR) of 3.47% from 2023 to 2033

INDIA, November 14, 2024

/EINPresswire.com/ -- The [Telmisartan Market](#)

refers to the pharmaceutical market for Telmisartan, a drug commonly used to treat hypertension (high blood pressure). Telmisartan is an angiotensin II receptor blocker (ARB) that works by relaxing the blood vessels, helping to lower blood pressure and enhance blood flow. This market encompasses the production, distribution, and sale of Telmisartan-based medications, as well as ongoing

research and development efforts focused on this drug. In addition to its primary use for controlling high blood pressure, Telmisartan is also prescribed to reduce the risk of stroke, heart attack, and death in individuals at high risk for cardiovascular events.

For More Information: <https://evolvebi.com/report/telmisartan-market-analysis/>

North America to maintain its dominance in 2023

North America holds a dominant position in the Telmisartan Market, primarily driven by the United States and Canada. Both countries have well-established healthcare systems, with a high level of awareness about hypertension and cardiovascular health. The market benefits from a large patient pool requiring antihypertensive treatments, particularly as the prevalence of hypertension continues to rise. In addition, the strong healthcare spending in these regions supports the availability and accessibility of Telmisartan-based medications. However, the market also faces significant generic competition due to the expiration of patents for Telmisartan, which has opened the door to cost-effective alternatives, impacting overall market



pricing dynamics. Despite this, the demand for high-quality branded medications and the ongoing need for effective hypertension management continue to fuel the market's growth in North America.

For sample report pages – <https://evolvebi.com/report/telmisartan-market-analysis/>

Fueling Growth: The Essential Ingredients

The Telmisartan Market has seen significant growth due to heightened awareness about the risks associated with hypertension and cardiovascular diseases, which has led to higher diagnosis rates and improved treatment adherence. This, in turn, has driven the demand for medications like Telmisartan. Furthermore, advancements in pharmaceutical technology and formulation techniques have enhanced the efficacy and tolerability of Telmisartan, making it a preferred choice for both healthcare providers and patients. The rising healthcare expenditure, particularly in developing countries, is further supporting the adoption of advanced medications such as Telmisartan. Ongoing research and development activities focused on improving existing treatments and developing new formulations of Telmisartan are also contributing to the market's expansion.

The future of Telmisartan Market

The global aging population is a key factor driving the demand for antihypertensive medications. As older adults are more susceptible to hypertension and cardiovascular conditions, this demographic trend is expected to significantly increase the need for Telmisartan. Additionally, growing awareness of hypertension, coupled with rising healthcare spending, especially in emerging economies, presents ample opportunities for market expansion. The adoption of digital health solutions and telemedicine is also enhancing patient access to healthcare services, potentially improving the diagnosis and treatment rates for hypertension. This trend is expected to benefit the Telmisartan market by increasing its reach and improving patient outcomes.

Get access to the report – <https://evolvebi.com/report/telmisartan-market-analysis/>

Core Market Segments

“The Hypertension segment is expected to grow faster throughout the forecast period. By Indication, the market is primarily driven by the Hypertension segment, which dominates the market. This is largely due to the increasing prevalence of hypertension, the rising demand for antihypertensive drugs, and growing awareness about hypertension and its management. Global campaigns and health initiatives focused on educating the public about hypertension are expected to further fuel the growth of this segment.”

“The Hospital Pharmacies segment is expected to grow faster throughout the forecast period. In terms of sales channels, the Hospital Pharmacies segment is the dominant player in the Telmisartan market. This is attributed to the expanding number of hospital pharmacies worldwide and the widespread accessibility of these pharmacies. Additionally, the growth of the segment is supported by the increasing number of hospitalized hypertension patients and the development of hospital pharmacy infrastructure, especially in developing countries such as

China and India. The availability of Telmisartan in hospital pharmacies ensures it reaches patients who are critically ill and require immediate access to medication.”

Market Dominators

Abbott Laboratories, Aurobindo Pharma, Boehringer Ingelheim International GmbH, Cipla Inc, Glaxosmithkline Plc, Mylan N.V., Sanofi, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd and Zydus Cadila.

Key Matrix for Latest Report Update

- Base Year: 2023
- Estimated Year: 2024
- CAGR: 2024 to 2034

About EvolveBI

[Evolve Business Intelligence](#) is a market research, business intelligence, and advisory firm providing innovative solutions to challenging pain points of a business. Our market research reports include data useful to micro, small, medium, and large-scale enterprises. We provide solutions ranging from mere data collection to business advisory.

Evolve Business Intelligence is built on account of technology advancement providing highly accurate data through our in-house AI-modelled data analysis and forecast tool – EvolveBI. This tool tracks real-time data including, quarter performance, annual performance, and recent developments from fortune’s global 2000 companies.

Swapnil Patel

Evolve Business Intelligence

swapnil@evolvebi.com

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/760474305>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.